GOG-3069
Clinical Trial Title | Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers |
Trial Status | Open to Enrollment |
Start Date | 02/28/2024 |
Location | hospitals |
Trial Type | Cancer - Adult Oncology |
Specific Condition | Endometrioid Endometrial Cancers |
Description | This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal. |
Eligibility Criteria | Eligible Patients
Please contact Legacy Oncology Research for additional study inclusion/exclusion information. |
IRB Number | Central IRB |
Notes | Study Details | A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | ClinicalTrials.gov |
Principal Investigator | Julia Fehniger, MD |
Contact Name | Oncology Clinical Research |
Contact Phone | 503-413-8199 |
Contact Fax | 503-413-6920 |
Contact E-Mail | oncologyresearch@lhs.org |